[Contributor name pending]

This entry is a structural placeholder for a clinical pharmacologist or translational researcher with direct experience interpreting human trial data for NAD+ precursors and related metabolic interventions. On assignment, the contributor filling this slot will hold primary review responsibility for any content making dosing, safety, or efficacy claims grounded in human evidence. Typical review scope includes: pharmacokinetic and pharmacodynamic profiles of NR, NMN, NAD+ IV, and related precursors; dose-response and ceiling-effect data from published RCTs; adverse event reporting and contraindication flags; drug-nutrient and supplement-drug interaction considerations; interpretation of surrogate endpoints (whole-blood NAD+, muscle NAD+, insulin sensitivity markers, walking distance, grip strength) versus clinical endpoints; and the translational limits of preclinical findings — flagging where mouse data has been over-extrapolated to human recommendations. The contributor is also responsible for reviewing content under /delivery (oral, sublingual, subcutaneous, IV, intranasal routes) for accuracy about bioavailability claims in humans specifically. Credentials, institutional affiliation, ORCID, and publication history will be added when a named individual is assigned. Until then, articles requiring clinical-pharmacology review default to the editorial-team collective byline.

Areas of expertise